Effects of ankylosing spondylitis on cardiovascular disease: aMendelian randomization study.

Lu Xiao, Shudian Lin, Feng Zhan
Author Information
  1. Lu Xiao: Department of Rheumatology, The Fifth People's Hospital of Wuxi, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, China.
  2. Shudian Lin: Department of Rheumatology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.
  3. Feng Zhan: Department of Rheumatology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.

Abstract

Objective: Accumulating evidence suggests that patients with ankylosing spondylitis (AS) have an elevated risk for cardiovascular disease (CVD) and cardiovascular death, however, whether AS has causal effects on the risk of CVD is unclear.Two-sample Mendelian randomization (MR) was utilizedto examine the probable causal link between them.
Methods: Summary statistics from publicly released genome-wide association studies (GWAS) was used to perform MR analyses. Genetically predicted AS was selected as the exposure variable from published GWAS meta-analyses. CVD was adopted as the outcome variable. The inverse variant weighted method was employed to obtain the casual estimates. The robustness of the results was also examined by evaluating the pleiotropy and heterogeneity of single-nucleotide polymorphisms.
Results: According to MR analyses, genetic susceptibility to AS was associated with a high risk of heart failure and ischemic stroke, while negativelygenetic susceptibility was found between AS and peripheral atherosclerosis. No statistical relationship was found between AS and venous thromboembolism, atrial fibrillation, coronary atherosclerosis, and valvular heart disease. Sensitivity analysis showed no evidence of horizontal pleiotropy or heterogeneity.
Conclusion: The present study suggests that AS exerts causal effects on the risk of CVD, including heart failure, ischemic stroke, and peripheral atherosclerosis.

Keywords

References

  1. Genet Epidemiol. 2016 May;40(4):304-14 [PMID: 27061298]
  2. Ann Rheum Dis. 2017 Jan;76(1):17-28 [PMID: 27697765]
  3. Front Immunol. 2022 Jun 06;13:908831 [PMID: 35734181]
  4. Int J Cancer. 2020 Oct 1;147(7):1895-1903 [PMID: 32215913]
  5. J Korean Neurosurg Soc. 2019 Mar;62(2):217-224 [PMID: 30840977]
  6. Curr Vasc Pharmacol. 2020;18(5):473-487 [PMID: 31330576]
  7. Dtsch Arztebl Int. 2017 Mar 24;114(12):197-203 [PMID: 28407841]
  8. Mult Scler. 2021 Dec;27(14):2150-2158 [PMID: 33749377]
  9. Ann Rheum Dis. 2017 Feb;76(2):364-370 [PMID: 27283333]
  10. Front Pharmacol. 2020 Nov 06;11:559593 [PMID: 33343345]
  11. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):612-20 [PMID: 23406817]
  12. J Lipid Res. 2011 Aug;52(8):1542-50 [PMID: 21572087]
  13. Int J Epidemiol. 2003 Feb;32(1):1-22 [PMID: 12689998]
  14. Semin Arthritis Rheum. 2012 Oct;42(2):140-5 [PMID: 22494565]
  15. Bioinformatics. 2019 Nov 1;35(22):4851-4853 [PMID: 31233103]
  16. Curr Pharm Des. 2018;24(3):262-280 [PMID: 29359662]
  17. Int J Rheum Dis. 2023 Feb;26(2):183-186 [PMID: 36703270]
  18. Int J Epidemiol. 2011 Jun;40(3):755-64 [PMID: 21414999]
  19. Int J Epidemiol. 2015 Apr;44(2):512-25 [PMID: 26050253]
  20. Nat Genet. 2018 May;50(5):693-698 [PMID: 29686387]
  21. Cell Physiol Biochem. 2019;52(4):681-695 [PMID: 30921507]
  22. Ann Rheum Dis. 1993 Mar;52(3):174-6 [PMID: 8484668]
  23. Clin Rheumatol. 2018 Apr;37(4):1053-1058 [PMID: 29473098]
  24. J Am Soc Echocardiogr. 2009 May;22(5):542.e5-7 [PMID: 19269784]
  25. Eur J Intern Med. 2011 Dec;22(6):554-60 [PMID: 22075279]
  26. Reumatologia. 2019;57(2):100-105 [PMID: 31130748]
  27. Acta Neurochir (Wien). 2018 May;160(5):949-955 [PMID: 29470721]
  28. Res Synth Methods. 2019 Dec;10(4):486-496 [PMID: 30861319]
  29. Biochem Biophys Res Commun. 2018 Jan 1;495(1):1356-1362 [PMID: 29146189]
  30. Acta Neurochir (Wien). 2018 May;160(5):959-961 [PMID: 29497832]
  31. Mol Biol Evol. 2015 Jan;32(1):268-74 [PMID: 25371430]
  32. Arthritis Rheum. 2011 Nov;63(11):3294-304 [PMID: 21834064]
  33. Rheumatol Int. 2013 Jul;33(7):1725-9 [PMID: 23283540]
  34. Lab Invest. 2017 Jan;97(1):4-13 [PMID: 27869795]
  35. Int J Neurosci. 2015;125(12):885-94 [PMID: 25375269]
  36. Int J Epidemiol. 2016 Dec 1;45(6):1961-1974 [PMID: 27616674]
  37. Arthritis Care Res (Hoboken). 2011 Apr;63(4):550-6 [PMID: 21452267]
  38. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S11-5 [PMID: 12463440]
  39. Semin Arthritis Rheum. 2014 Aug;44(1):14-9 [PMID: 24655534]
  40. Ther Adv Musculoskelet Dis. 2021 Jun 18;13:1759720X211021676 [PMID: 34211590]

Word Cloud

Created with Highcharts 10.0.0ASriskcardiovascularCVDheartankylosingspondylitisdiseasecausalrandomizationMRfailureischemicstrokeatherosclerosisevidencesuggestseffectsMendelianGWASanalysesvariablepleiotropyheterogeneitysusceptibilityfoundperipheralstudyObjective:AccumulatingpatientselevateddeathhoweverwhetherunclearTwo-sampleutilizedtoexamineprobablelinkthemMethods:Summarystatisticspubliclyreleasedgenome-wideassociationstudiesusedperformGeneticallypredictedselectedexposurepublishedmeta-analysesadoptedoutcomeinversevariantweightedmethodemployedobtaincasualestimatesrobustnessresultsalsoexaminedevaluatingsingle-nucleotidepolymorphismsResults:AccordinggeneticassociatedhighnegativelygeneticstatisticalrelationshipvenousthromboembolismatrialfibrillationcoronaryvalvularSensitivityanalysisshowedhorizontalConclusion:presentexertsincludingEffectsdisease:aMendelian

Similar Articles

Cited By